Abstract
Purpose
To investigate the effects of onabotulinum toxin type A (Onabot/A) intravesical injections on urinary and sexual function in a group of patients affected by multiple sclerosis (MS).
Methods
We enrolled 31 MS female patients with symptoms of overactive bladder and detrusor overactivity. All patients underwent urodynamics and were administered 3-day voiding diary, Incontinence Quality of Life (I-QoL) questionnaire, Female Sexual Function Index (FSFI) questionnaire, Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Depression Rating Scale (HAM-D) before and 3 months after Onabot/A intravesical injection.
Results
Onabot/A injection significantly improved urinary symptoms as shown by the 3-day voiding diary, I-QoL questionnaire and the urodynamic variables. In addition, it also significantly improved sexual functioning in continent patients and psychological status as demonstrated by the increase in FSFI, HAM-A and HAM-D scores.
Conclusions
The Onabot/A-induced positive effect on sexual dysfunction in our MS patients is likely due to an indirect effect exerted by the overall urological clinical improvement on sexual function at both the psychological and emotional levels. The positive effect exerted by Onabot/A on the anxiety and depression scale also suggests that urinary symptoms have a negative impact on the psychological status of the patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tepavcevic DK, Kostic J, Basoroski ID, Stojsavljevic N, Pekmezovic T, Drulovic J (2008) The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler 14:1131–1136
Kessler TM, Fowler CJ, Panicker JN (2009) Sexual dysfunction in multiple sclerosis. Expert Rev Neurother 9:341–350
DasGupta R, Fowler CJ (2003) Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 63:153–166
Donzé C, Hautecoeur P (2009) Urinary, sexual, and bowel disorders in early-stage multiple sclerosis. Rev Neurol 165:148–155
Proietti S, Giannantoni A, Sahai A, Khan MS, Dasgupta P (2012) Overactive bladder and sexual function: a nightmare couple. BJU Int 11:921–924
Rogers RG (2013) Sexual function in women with pelvic floor disorders. Can Urol Assoc J 7:199–201
Hajebrahimi S, Azaripour A, Sadeghi-Bazargani HJ (2008) Tolterodine immediate release improves sexual function in women with overactive bladder. J Sex Med 5:2880–2885
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12:189–198
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
Rosen R, Brawn C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino RJ (2000) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26:191–208
Hamilton M (1959) The assessment of anxiety states by ratings. Br J Med Psychol 32:50–55
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C (2013) OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn 32:1109–1115
Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV (2006) The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 195:1730–1735
Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 62:816–830
Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C (2014) An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 65:981–990
Yih JM, Killinger KA, Boura JA, Peters KM (2013) Changes in sexual functioning in women after neuromodulation for voiding dysfunction. J Sex Med. 10:2477–2483
Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA (2011) The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med 8:1603–1615
Salonia A, Zanni G, Nappi RE, Briganti A, Dehò F, Fabbri F et al (2004) Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. Eur Urol 45:642–648
Wehbe SA, Kellogg S, Whitmore K (2010) Urogenital complaints and female sexual dysfunction. J Sex Med 7:2304–2317
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standard
This study has been approved by the ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent
All persons included in the present study gave their informed consent prior to their inclusion in the study.
Author information
Authors and Affiliations
Corresponding author
Additional information
Antonella Giannantoni and Antonella Conte have equally contributed to this work.
Rights and permissions
About this article
Cite this article
Giannantoni, A., Proietti, S., Giusti, G. et al. OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results. World J Urol 33, 2095–2101 (2015). https://doi.org/10.1007/s00345-015-1578-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-015-1578-4